Details
| Translated title of the contribution | Cost-Effectiveness of Pharmacological Smoking Cessation Therapies - A Systematic Literature Review |
|---|---|
| Original language | German |
| Pages (from-to) | 660-671 |
| Number of pages | 12 |
| Journal | GESUNDHEITSWESEN |
| Volume | 78 |
| Issue number | 10 |
| Early online date | 8 May 2015 |
| Publication status | Published - Oct 2016 |
Abstract
Aim of the Study: Through the promotion of smoking cessation premature mortality can be prevented. Therefore it is necessary to provide effective and cost-effective smoking cessation interventions. In Germany the cost of pharmacological smoking cessation measures are not yet reimbursed by the statutory health insurance. The aim of this study is to present the evidence on the cost-effectiveness of already approved pharmacological smoking cessation therapies and to evaluate their quality. Method: A systematic literature research was conducted in the databases by DIMDI (Medline, Embase, etc.) in April 2013 (update April 2014). The study research was focused on studies for cost effectiveness of nicotine replacement therapy (NRT), varenicline and bupropion. The assessment of study quality was performed using the quo;Quality of Health Economic Studies (QHES) instrument. Results: 33 Of the original 10 340 identified studies were finally included. The majority of the studies show that an additional prescription of NRT or bupropion to a medical consultation is a cost-effective strategy. In addition, in most studies varenicline is a dominant strategy compared to bupropion. Overall, the study quality was found to be very heterogeneous between 45 and 80 points (O 63.7 points). Conclusion: The studies show that treatment with varenicline is the most cost effective strategy followed by bupropion and the NRT. However, the studies can only be compared inadequately due to different levels of age and country-specific intervention costs.
ASJC Scopus subject areas
- Medicine(all)
- Public Health, Environmental and Occupational Health
Sustainable Development Goals
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: GESUNDHEITSWESEN, Vol. 78, No. 10, 10.2016, p. 660-671.
Research output: Contribution to journal › Article › Research › peer review
}
TY - JOUR
T1 - Kosteneffektivität von pharmakologischen Raucherentwöhnungsmaßnahmen
T2 - ein systematisches Literaturreview
AU - Aumann, I.
AU - Rozanski, K.
AU - Damm, K.
AU - Graf Von Der Schulenburg, J. M.
PY - 2016/10
Y1 - 2016/10
N2 - Aim of the Study: Through the promotion of smoking cessation premature mortality can be prevented. Therefore it is necessary to provide effective and cost-effective smoking cessation interventions. In Germany the cost of pharmacological smoking cessation measures are not yet reimbursed by the statutory health insurance. The aim of this study is to present the evidence on the cost-effectiveness of already approved pharmacological smoking cessation therapies and to evaluate their quality. Method: A systematic literature research was conducted in the databases by DIMDI (Medline, Embase, etc.) in April 2013 (update April 2014). The study research was focused on studies for cost effectiveness of nicotine replacement therapy (NRT), varenicline and bupropion. The assessment of study quality was performed using the quo;Quality of Health Economic Studies (QHES) instrument. Results: 33 Of the original 10 340 identified studies were finally included. The majority of the studies show that an additional prescription of NRT or bupropion to a medical consultation is a cost-effective strategy. In addition, in most studies varenicline is a dominant strategy compared to bupropion. Overall, the study quality was found to be very heterogeneous between 45 and 80 points (O 63.7 points). Conclusion: The studies show that treatment with varenicline is the most cost effective strategy followed by bupropion and the NRT. However, the studies can only be compared inadequately due to different levels of age and country-specific intervention costs.
AB - Aim of the Study: Through the promotion of smoking cessation premature mortality can be prevented. Therefore it is necessary to provide effective and cost-effective smoking cessation interventions. In Germany the cost of pharmacological smoking cessation measures are not yet reimbursed by the statutory health insurance. The aim of this study is to present the evidence on the cost-effectiveness of already approved pharmacological smoking cessation therapies and to evaluate their quality. Method: A systematic literature research was conducted in the databases by DIMDI (Medline, Embase, etc.) in April 2013 (update April 2014). The study research was focused on studies for cost effectiveness of nicotine replacement therapy (NRT), varenicline and bupropion. The assessment of study quality was performed using the quo;Quality of Health Economic Studies (QHES) instrument. Results: 33 Of the original 10 340 identified studies were finally included. The majority of the studies show that an additional prescription of NRT or bupropion to a medical consultation is a cost-effective strategy. In addition, in most studies varenicline is a dominant strategy compared to bupropion. Overall, the study quality was found to be very heterogeneous between 45 and 80 points (O 63.7 points). Conclusion: The studies show that treatment with varenicline is the most cost effective strategy followed by bupropion and the NRT. However, the studies can only be compared inadequately due to different levels of age and country-specific intervention costs.
KW - bupropion
KW - cost-effectiveness
KW - nicotine
KW - pharmacological smoking cessation therapies
KW - vareniclin
UR - http://www.scopus.com/inward/record.url?scp=84994031541&partnerID=8YFLogxK
U2 - 10.1055/s-0035-1548852
DO - 10.1055/s-0035-1548852
M3 - Artikel
C2 - 27784123
AN - SCOPUS:84994031541
VL - 78
SP - 660
EP - 671
JO - GESUNDHEITSWESEN
JF - GESUNDHEITSWESEN
SN - 0941-3790
IS - 10
ER -